ST
VRTX icon

Sageworth Trust’s Vertex Pharmaceuticals VRTX Stock Holding History

Sageworth Trust’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-481
Closed -$215K – 178
2026
Q1 		$215K Buy
+481
New +$224K 0.01% 165
2025
Q4 		– Sell
-561
Closed -$220K – 265
2025
Q3 		$220K Buy
+561
New +$234K 0.01% 251
2024
Q3 		– Sell
-762
Closed -$357K – 129
2024
Q2 		$357K Buy
+762
New +$331K 0.02% 89
2018
Q1 		– Sell
-7
Closed -$1K – 189
2017
Q4 		$1K Buy
+7
New +$1.04K ﹤0.01% 115

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Sageworth Trust's VRTX Position: Q2 2026 in Review

Sageworth Trust sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 481 shares — an estimated $215K sold.

Sageworth Trust first reported a position in VRTX in Q4 2017 and held it in 4 quarters. The position peaked at $357K in Q2 2024. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Sageworth Trust reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Sageworth Trust sold 481 Vertex Pharmaceuticals shares in Q2 2026, an estimated $215K.
  • Sageworth Trust first reported a position in Vertex Pharmaceuticals in Q4 2017 and held it in 4 quarters.
  • Sageworth Trust's Vertex Pharmaceuticals position peaked at $357K in Q2 2024.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Sageworth Trust's 13F filing for Q2 2026, filed 28 Jul 2026.